XML 51 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Components (Tables)
 12 Months Ended
Dec. 31, 2022
Balance Sheet Components [Abstract]  
Cash and Restricted Cash
Cash and restricted cash
(In millions)December 31,
2022		December 31,
2021		December 31,
2020
Cash and cash equivalents$1,259.9 $701.2 $844.4 
Restricted cash, included in other current and non-current assets2.6 5.0 5.6 
Cash, cash equivalents and restricted cash$1,262.5 $706.2 $850.0 
Inventories
Inventories
(In millions)December 31, 2022December 31, 2021
Raw materials$571.5 $922.4 
Work in process755.4 993.3 
Finished goods2,192.6 2,062.0 
Inventories$3,519.5 $3,977.7 
Prepaid expenses and other current assets
Prepaid expenses and other current assets
(In millions)December 31, 2022December 31, 2021
Prepaid expenses$194.6 $256.7 
Available-for-sale fixed income securities35.3 38.2 
Fair value of financial instruments134.7 144.6 
Equity securities42.6 51.0 
Other current assets1,404.0 1,467.1 
Prepaid expenses and other current assets$1,811.2 $1,957.6 
Property, plant and equipment, net
Property, plant and equipment, net
(In millions)December 31, 2022December 31, 2021
Machinery and equipment$2,936.7 $3,054.0 
Buildings and improvements1,539.7 1,808.5 
Construction in progress474.0 588.7 
Land and improvements133.4 137.9 
Gross property, plant and equipment5,083.8 5,589.1 
Accumulated depreciation2,059.3 2,400.5 
Property, plant and equipment, net$3,024.5 $3,188.6 
Other assets
Other assets
(In millions)December 31, 2022December 31, 2021
CCPS in Biocon Biologics$997.4 $— 
Operating lease right-of-use assets259.3 290.8 
Non-marketable equity investments94.0 81.4 
Deferred consideration due from Biocon Biologics299.5 — 
Other long-term assets753.3 798.5 
Other assets$2,403.5 $1,170.7 
Accounts payable
Accounts payable
(In millions)December 31, 2022December 31, 2021
Trade accounts payable$1,158.0 $1,056.1 
Other payables608.6 601.3 
Accounts payable$1,766.6 $1,657.4 
Other current liabilities
Other current liabilities
(In millions)December 31, 2022December 31, 2021
Accrued sales allowances$888.8 $1,362.1 
Payroll and employee benefit liabilities 746.8 741.9 
Legal and professional accruals, including litigation accruals297.2 715.6 
Contingent consideration64.4 66.7 
Accrued restructuring95.3 233.5 
Accrued interest80.2 86.6 
Fair value of financial instruments187.0 61.0 
Operating lease liability80.6 86.7 
Due to Biocon Biologics22.5 — 
Other978.1 1,265.5 
Other current liabilities$3,440.9 $4,619.6 
Other long-term obligations
(In millions)December 31, 2022December 31, 2021
Employee benefit liabilities$544.6 $876.4 
Contingent consideration (1)
310.6 133.0 
Tax related items, including contingencies414.6 426.1 
Operating lease liability181.4 200.9 
Accrued restructuring60.4 64.3 
Other244.9 232.9 
Other long-term obligations$1,756.5 $1,933.6 
(1)    Includes a total of $221.2 million due to Biocon Biologics. Refer to Note 10 Financial Instruments and Risk Management for additional information.